- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07483320
Extracorporale Shockwave Therapie en Platelet-Rijk Plasma voor Midportion Achilles Tendinopathie
Een gerandomiseerd gecontroleerd onderzoek naar de invloed van fysiotherapie, shockwavetherapie, plaatjesrijk plasma of gecombineerde behandeling bij de behandeling van middenportie achillespees tendinopathie
Midportion Achilles tendinopathy is a common cause of pain and functional limitation in both athletes and the general population. Progressive tendon loading programs are considered first-line treatment but do not lead to satisfactory outcomes in all patients. Extracorporeal shockwave therapy (ESWT) and platelet-rich plasma (PRP) injections are commonly used interventions for refractory symptoms, yet evidence supporting their combined use is limited particularly in treating Achilles tendon disorders.
This randomized controlled trial will evaluate the effectiveness of a standardized exercise program alone or in combination with PRP injection, ESWT, or both therapies in active adults with midportion Achilles tendinopathy. Participants will be randomized to one of four treatment groups and followed for six months. The primary outcome will assess changes in Achilles tendon symptoms and function using the Victorian Institute of Sport Assessment-Achilles (VISA-A) score. Secondary outcomes will include patient-reported outcomes, physical function testing, ultrasound tendon structure measures, and gait biomechanics.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Midportion Achilles tendinopathy (Mid-AT) is characterized by pain, stiffness, and impaired function resulting from a failed tendon healing response. Progressive loading exercise programs such as the Silbernagel protocol represent the current standard treatment and provide meaningful improvement for many individuals. However, approximately 40% of patients continue to experience persistent symptoms despite rehabilitation.
Extracorporeal shockwave therapy (ESWT) and platelet-rich plasma (PRP) injections are increasingly used in clinical practice to address refractory symptoms. ESWT is proposed to stimulate tissue healing through mechanotransduction and has demonstrated improved outcomes when combined with exercise therapy in some studies. PRP contains concentrated autologous growth factors that may enhance tendon healing through stimulation of extracellular matrix production, angiogenesis, and collagen synthesis.
Despite increasing clinical use, there remains limited evidence evaluating the comparative or combined effects of PRP and ESWT in the treatment of Achilles tendinopathy. Furthermore, few trials have evaluated these therapies within a standardized rehabilitation framework.
The purpose of this randomized controlled trial is to evaluate the effectiveness of exercise therapy alone compared with exercise therapy combined with PRP injection, ESWT, or both interventions in individuals with chronic midportion Achilles tendinopathy. Participants will be randomized to one of four treatment groups: exercise with sham procedures (control), exercise plus PRP injection, exercise plus ESWT, or exercise combined with PRP and ESWT. Participants will be followed for six months to evaluate patient-reported outcomes, tendon structure using ultrasound, physical function testing, and gait biomechanics. This study aims to determine whether PRP, ESWT, or the combination of both treatments provide superior functional recovery compared with exercise-based rehabilitation alone.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Sydney Karnovsky, MD
- Telefoonnummer: (862) 216-8050
- E-mail: skarnovsky@mgb.org
Studie Locaties
-
-
Massachusetts
-
Cambridge, Massachusetts, Verenigde Staten, 02138
- Spaulding Cambridge Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 18-65 years
- Diagnosis of unilateral midportion Achilles tendinopathy
- Symptoms present for more than 3 months
- VISA-A score <80 at baseline
- Pre-injury physical activity level ≥3 on the Physical Activity Scale
- Ability to participate in rehabilitation program
Exclusion Criteria:
- Symptoms present for less than 3 months
- Prior PRP injection or ESWT treatment to the Achilles tendon within 3 months
- Other lower extremity musculoskeletal injury affecting function
- Symptomatic arthritis affecting the ankle or foot
- Rheumatologic disease or connective tissue disorder
- Coagulopathy or anticoagulant therapy affecting platelet function
- Neuropathy affecting pain perception
- Known cardiac condition contraindicating treatment
- Poorly controlled diabetes (HbA1c >9.0)
- Pregnancy
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Sham-vergelijker: Arm 1 - Control Exercise Therapy + Sham PRP + Sham Shockwave
A sham PRP injection will be performed where the needle breaks the skin but does not fenestrate the tendon. The sham ESWT will include radial pressure waves and focused shockwaves delivered without the device turned on to deliver energy and audio recording. Standard of care exercise program will be prescribed to participants with four stages to be performed during the study. |
A needle will be inserted but no injection will occur around the Achilles tendon Both focused shockwave and radial pressure wave will be in contact with the skin, but the devices will not be active to deliver energy. An audio recording will provide noises similar to the machines operating. |
|
Experimenteel: Arm 2 - Exercise Therapy + Platelet-Rich Plasma (PRP) + Sham Shockwave
PRP will be delivered around the tendon, sham ESWT will be issued. Standard of care exercise program will be prescribed to participants with four stages to be performed during the study. |
Both focused shockwave and radial pressure wave will be in contact with the skin, but the devices will not be active to deliver energy. An audio recording will provide noises similar to the machines operating. Participants randomized to PRP will receive a single ultrasound-guided injection of approximately 3 mL of neutrophil-poor platelet-rich plasma derived from autologous blood. Blood will be processed to concentrate platelets and the PRP will be injected adjacent to the Achilles tendon at the site of maximal pain. |
|
Experimenteel: Arm 3 - Exercise Therapy + Extracorporeal Shockwave Therapy (ESWT) + Sham PRP
Sham PRP will be delivered. Three sessions of ESWT will be delivered to the Achilles tendon. Standard of care exercise program will be prescribed to participants with four stages to be performed during the study. |
A needle will be inserted but no injection will occur around the Achilles tendon Participants randomized to ESWT will receive three weekly treatment sessions. Focused shockwave therapy will deliver approximately 2000 shocks with gradual energy escalation, followed by radial shockwave therapy delivering approximately 3000 pulses to the Achilles tendon and 3000 pulses to surrounding musculature. |
|
Experimenteel: Arm 4 - Exercise Therapy + Platelet-Rich Plasma + Extracorporeal Shockwave Therapy
PRP will be administered followed by three sessions of ESWT. Standard of care exercise program will be prescribed to participants with four stages to be performed during the study. |
Participants randomized to PRP will receive a single ultrasound-guided injection of approximately 3 mL of neutrophil-poor platelet-rich plasma derived from autologous blood. Blood will be processed to concentrate platelets and the PRP will be injected adjacent to the Achilles tendon at the site of maximal pain. Participants randomized to ESWT will receive three weekly treatment sessions. Focused shockwave therapy will deliver approximately 2000 shocks with gradual energy escalation, followed by radial shockwave therapy delivering approximately 3000 pulses to the Achilles tendon and 3000 pulses to surrounding musculature. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Victorian Institute of Sport Assessment-Achilles (VISA-A)
Tijdsspanne: baseline, 8 weeks, 4 months, 6 months
|
The VISA-A is an eight item questionnaire measures Achilles tendon pain and function, with scores ranging from 0 to 100 (higher scores indicating better function). |
baseline, 8 weeks, 4 months, 6 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
PROMIS-29 Patient Reported Outcomes
Tijdsspanne: Baseline, 8 weeks, 4 months, 6 months
|
Change in PROMIS-29 domain scores evaluating physical function, pain interference, fatigue, sleep disturbance, anxiety, depression, and social participation. |
Baseline, 8 weeks, 4 months, 6 months
|
|
University of Wisconsin Running Injury and Recovery Index (UWRI)
Tijdsspanne: baseline, 8 weeks, 4 months, 6 months
|
Running-specific recovery and functional ability measure for participants who run regularly. |
baseline, 8 weeks, 4 months, 6 months
|
|
Ultrasound Tendon Cross-Sectional Area
Tijdsspanne: baseline, 6 months
|
Changes in Achilles tendon cross-sectional area measured by ultrasound at the site of maximal tendon thickness. |
baseline, 6 months
|
|
Heel Rise Test Endurance
Tijdsspanne: baseline, 6 months
|
Total number of single-leg heel raises performed until fatigue or inability to maintain pace or same height. |
baseline, 6 months
|
|
Hop Test Pain
Tijdsspanne: baseline, 6 months
|
Pain rating following completion of a standardized single-leg hop test of 20 repetitions. |
baseline, 6 months
|
|
Gait Biomechanics
Tijdsspanne: baseline, 6 months
|
Changes in lower extremity biomechanics and symmetry during walking and running assessed using motion capture and instrumented treadmill analysis in those who elect to complete biomechanical assessment. |
baseline, 6 months
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Adam S. Tenforde, MD, Spaulding Rehabiltaition Hospital
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2025P002308
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
No identifiable information will be shared outside Mass General Brigham. We will consider publishing a limited deidentified data set at time of publication of our findings.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .